Watson Bio announced that Zhang Li, the secretary of the company's board of directors, was liened for investigation by the Wenshan Prefecture Supervision Commission in Yunnan Province for personal reasons

Recently, Watson Bio announced that Zhang Li, the secretary of the company's board of directors, was placed in custody for investigation by the Wenshan Prefecture Supervision Commission of Yunnan Province for personal reasons

Recently, Watson Bio announced that Zhang Li, the secretary of the company's board of directors, was placed in custody for investigation by the Wenshan Prefecture Supervision Commission of Yunnan Province for personal reasons

Why was Zhang Li liened for investigation by the Wenshan Prefecture Supervision Commission? Watson Bio said in the announcement that it has not yet been informed of the progress and conclusion of the lien investigation, and the company will continue to pay attention to the follow-up of the above matters

The annual salary before tax is nearly 3 million

Pre-tax annual salary of nearly 3 million pre-tax annual salary of nearly 3 million pre-tax annual salary of nearly 3 million

According to public information, Zhang Li is 45 years old this year, and in 2017, after being nominated by chairman Li Yunchun, he served as the secretary of the board of directors of Watson Biologics

According to public information, Zhang Li is 45 years old this year, and in 2017, after being nominated by chairman Li Yunchun, he served as the secretary of the board of directors of Watson Biologics

Source: Watson Biotech 2021 Annual Report

Source: Watson Biotech 2021 Annual Report

It is worth mentioning that on December 5, 2018, Zhang Li was taken by the Yunnan Securities Regulatory Bureau to issue a warning letter for information disclosure violations

It is worth mentioning that on December 5, 2018, Zhang Li was taken by the Yunnan Securities Regulatory Bureau to issue a warning letter for information disclosure violations

In fact, before serving as the secretary of the board of directors of Watson Biology, Zhang Li worked in the Yunnan State-owned Assets System for a long time, and served as the deputy director of the Yunnan Stone Forest Scenic Area Management Bureau, the director of the office of Yunnan City Investment and Real Estate Co.

In fact, before serving as the secretary of the board of directors of Watson Biology, Zhang Li worked in the Yunnan State-owned Assets System for a long time, and served as the deputy director of the Yunnan Stone Forest Scenic Area Management Bureau, the director of the office of Yunnan City Investment and Real Estate Co.

In 2017, when Zhang Li was hired as the secretary of the board of directors of Watson Biologics, the largest shareholder of Watson Biologics was Yunnan Industrial Investment Holding Group

In 2017, when Zhang Li was hired as the secretary of the board of directors of Watson Biologics, the largest shareholder of Watson Biologics was Yunnan Industrial Investment Holding Group

Recent downturns

Recent downturn Recent trend downturn Recent trend downturn Recent trend downturn

Watson Bio is the first enterprise in Yunnan Province to be listed on the China Growth Enterprise Market (GEM), and is in a leading position in the field of biotechnology drugs represented by new vaccines

Watson Bio is the first enterprise in Yunnan Province to be listed on the China Growth Enterprise Market (GEM), and is in a leading position in the field of biotechnology drugs represented by new vaccines
.

In the first half of 2022, Watson Bio's operating income was 2.
348 billion yuan, an increase of 73.
96% year-on-year; Net profit was 421 million, an increase of 31.
90%
year-on-year.
Net profit in the second quarter increased by 890.
12%
sequentially.

In the first half of 2022, Watson Bio's operating income was 2.
348 billion yuan, an increase of 73.
96% year-on-year; Net profit was 421 million, an increase of 31.
90%
year-on-year.
Net profit in the second quarter increased by 890.
12%
sequentially.

As for the reasons for the increase in operating income, Watson Bio said that it is mainly due to the increase in sales of 13-valent pneumonia conjugate vaccine and the increase in sales of the company's new bivalent HPV vaccine
.
It should be pointed out that the 13-valent pneumococcal polysaccharide conjugate vaccine is the first domestic vaccine independently developed and produced in China, and it is also the second product
in the world.

As for the reasons for the increase in operating income, Watson Bio said that it is mainly due to the increase in sales of 13-valent pneumonia conjugate vaccine and the increase in sales of the company's new bivalent HPV vaccine
.
It should be pointed out that the 13-valent pneumococcal polysaccharide conjugate vaccine is the first domestic vaccine independently developed and produced in China, and it is also the second product
in the world.

In March this year, Watson Biobial Bivalent HPV Vaccine was approved, and the number of vaccine products listed by the company reached 8 (12 specifications).

In March this year, Watson Biobial Bivalent HPV Vaccine was approved, and the number of vaccine products listed by the company reached 8 (12 specifications).

In addition, according to the Insight database, Watson currently has 5 new crown vaccines in research, and the technical route covers recombinant new coronavirus protein vaccines, adenovirus vaccines, and mRNA vaccines; Coverage of mutation types includes both conventional vaccines and vaccines developed for mutant strains
.

In addition, according to the Insight database, Watson currently has 5 new crown vaccines in research, and the technical route covers recombinant new coronavirus protein vaccines, adenovirus vaccines, and mRNA vaccines; Coverage of mutation types includes both conventional vaccines and vaccines developed for mutant strains
.

Despite this, Watson Bio's recent stock price has still fallen, and since it came out of the peak of 87.
28 yuan / share on August 30 last year, there has been a continuous swing decline
.
As of the close of trading on September 6, Watson Bio's stock price closed at 41.
38 yuan / share, and the latest market value was 66.
29 billion yuan
.
In the past year, the company's stock price has fallen by more than 50%.

Despite this, Watson Bio's recent stock price has still fallen, and since it came out of the peak of 87.
28 yuan / share on August 30 last year, there has been a continuous swing decline
.
As of the close of trading on September 6, Watson Bio's stock price closed at 41.
38 yuan / share, and the latest market value was 66.
29 billion yuan
.
In the past year, the company's stock price has fallen by more than 50%.